Chikungunya virus (CHIKV) is a mosquito-borne human pathogen that affects millions of
individuals each year by causing non-specific flu-like symptoms, with a characteristic rash accompanied
by joint pain that may last for a long time after the resolution of the infection. Despite intense research
efforts, no approved vaccine or antiviral therapy is yet available. This review is based on articles
retrieved by PubMed and clinical trials since 1980 to present. Virus complexity, protective and non-protective immune
responses against the virus, and the most important a new patented approaches for Chikungunya vaccine development
Keywords: Chikungunya virus, DNA vaccines, immune response, vaccines, virus particles, viral vectors.
Rights & PermissionsPrintExport